Cystinuria Market: Industry Analysis, Treatment, Pipeline Drugs and Key Companies By DelveInsight| Bausch Health, Mission Pharmacal, Retrophin, Advicenne and Many Others

 Breaking News
  • No posts were found

Cystinuria Market: Industry Analysis, Treatment, Pipeline Drugs and Key Companies By DelveInsight| Bausch Health, Mission Pharmacal, Retrophin, Advicenne and Many Others

July 14
21:42 2021
Cystinuria Market: Industry Analysis, Treatment, Pipeline Drugs and Key Companies By DelveInsight| Bausch Health, Mission Pharmacal, Retrophin, Advicenne and Many Others

Cystinuria Market

Cystinuria is an inherited metabolic disorder characterized by the abnormal movement (transport) in the intestines and kidneys, of certain organic chemical compounds (amino acids). These include cystine, lysine, arginine, and ornithine. Excessive amounts of undissolved cysteine in the urine (cystinuria) cause the formation of stones (calculi) in the kidney, bladder, or ureter.


DelveInsight’s ‘Cystinuria Market Insight, Epidemiology and Market Forecast – 2030′ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Cystinuria in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Cystinuria from 2018 to 2030 segmented by seven major markets. 


Some Key Facts of Cystinuria Market:

  • As per DelveInsight estimates, total cases of Cystinuria in the 7MM was found to be 87,311 in 2020. Among all the countries, the estimates show population of Cystinuria in the United States to be ~33,265 in 2020.
  • Among the EU5 countries, Germany had the highest prevalent population of Cystinuria followed by France. On the other hand, Spain had the lowest prevalent population.
  • The Cystinuria is found to be more prevalent in females as compared to males. In 2020, there were 17,764 prevalent cases of Cystinuria in females and 15,502 prevalent cases in males in the United States and as per DelveInsight’s analysts assessments, in both the genders same trend is seen in all the countries of 7MM.
  • In type specific cases, maximum cases belong to Type B Cystinuria with 47% cases, while in Europe Type A is found to be more prevalent, while in Japan about 85.9% of cases belong to Type B Cystinuria.


Request for Free Sample Request:


Key benefits of the Cystinuria Market Report:

  • Cystinuria market report covers a descriptive overview and comprehensive insight of the Cystinuria epidemiology and Cystinuria market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  • Cystinuria market report provides insights on the current and emerging therapies.
  • Cystinuria market report provides a global historical and forecasted market covering drug outreach in 7MM.
  • Cystinuria market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cystinuria market.


“Cystinuria as a cause of 1–2% of stones observed in adults and about 10% of those occurring in children.”


The primary objective of Cystinuria treatment is to reduce the cystine concentration in the urine. The foremost aim of cystinuria treatment is to prevent the formation of the stone. The first line of treatment is high-fluid intake, which prevents the formation of new stones and dissolves the previously formed ones. By increasing the volume of urine, the concentration of cystine in the urine is reduced which prevents cystine from precipitating from the urine and forming stones.

Another strategy that has been attempted for cystinuria treatment is alkalization of the urine. The rationale is that in an alkaline (nonacidic) liquid, cystine tends to stay in solution and there it does no harm. Another approach for cystinuria treatment is the administration of D-penicillamine. D-penicillamine promotes the formation of cystine in a different chemical form (mixed disulfide), which is more soluble in the urine and is excreted easily.


Cystinuria Therapies are:

  • Cuprimine (d-penicillamine)
  • Tiopronin (Thiola)
  • ADV7103
  • Bucillamine
  • Tolvaptan
  • And many others


Request for Free Sample Request:


Cystinuria Companies Covered:

  • Bausch Health
  • Mission Pharmacal
  • Retrophin
  • Advicenne
  • Revive Therapeutics
  • Otsuka Pharmaceutical
  • And Many Others


Table of contents

1. Key Insights

2. Executive Summary of Cystinuria

3. Competitive Intelligence Analysis for Cystinuria

4. Cystinuria : Market Overview at a Glance

5. Cystinuria : Disease Background and Overview

6. Patient Journey

7. Cystinuria Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Cystinuria Treatment

11. Marketed Products

12. Emerging Therapies

13. Cystinuria: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Cystinuria

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life science. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Related Articles